Valneva SE

Valneva Provides Updated 2023 Financial Guidance

29 Dec 2023 15:30:00 By Nasdaq GlobeNewswire

Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors

20 Dec 2023 10:45:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights - November 30, 2023

06 Dec 2023 01:30:00 By Nasdaq GlobeNewswire

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15

04 Dec 2023 15:20:00 By Nasdaq GlobeNewswire

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

04 Dec 2023 00:00:00 By Nasdaq GlobeNewswire

EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

27 Nov 2023 00:00:00 By Nasdaq GlobeNewswire

Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors

15 Nov 2023 00:30:00 By Nasdaq GlobeNewswire

Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®

10 Nov 2023 00:00:00 By Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates

09 Nov 2023 00:00:00 By Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference

07 Nov 2023 00:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: October 31, 2023

06 Nov 2023 01:30:00 By Nasdaq GlobeNewswire

Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment

25 Oct 2023 11:15:00 By Nasdaq GlobeNewswire

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

11 Oct 2023 10:45:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: September 30, 2023

05 Oct 2023 01:30:00 By Nasdaq GlobeNewswire

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million

25 Sep 2023 00:00:00 By Nasdaq GlobeNewswire

Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

21 Sep 2023 00:00:00 By Nasdaq GlobeNewswire

Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

07 Sep 2023 00:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: August 31, 2023

06 Sep 2023 01:30:00 By Nasdaq GlobeNewswire

Valneva to Participate in Investor Conferences in the United States and Europe in September 2023

31 Aug 2023 12:00:00 By Nasdaq GlobeNewswire

Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review

29 Aug 2023 00:00:00 By Nasdaq GlobeNewswire